Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Finger Prick Test Could Transform Heart Attack Prevention

By HospiMedica International staff writers
Posted on 14 Feb 2025

Currently, blood-thinning medications are prescribed only to patients who have already experienced a heart attack or stroke, as these drugs can lead to serious bleeding in some individuals. More...

Due to the lack of a reliable method to predict who may benefit or be harmed by these medications, doctors have been unable to prescribe them preventively to high-risk patients. Now, a new study suggests that a simple scoring system could transform how doctors prevent heart attacks and strokes by identifying patients who are most likely to benefit from preventive treatment.

The innovative test, known as the TRIPLE Score, was developed by researchers at the University of Reading (Berkshire, UK). It measures specific proteins on blood platelets, along with the patient's age, to help doctors make better-informed decisions about prescribing blood-thinning medications like aspirin and clopidogrel. Although the test is not yet widely available, the goal is to eventually make it suitable for point-of-care use. It will be incorporated into patient studies to verify its potential to enhance care.

In their study, published in Circulation Research, the team demonstrated that the TRIPLE Score effectively identified patients whose blood was more prone to forming clots in laboratory tests. The findings also correlated with established risk scores used by doctors to estimate a patient’s likelihood of having a heart attack within the next 10 years. The test requires just a small blood sample and could be developed into a simple tool that healthcare providers, not just specialists, could use in practice.

“Our new test will help doctors make sure that patients receive the best treatment and keep their quality of life,” said Dr. Alexander Bye, lead author of the research at the University of Reading. “Next, we aim to make the test even easier to use by developing a finger prick test, so that it as simple as measuring blood glucose."


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.